Technical Analysis for SNG - Synairgen Plc

Grade Last Price % Change Price Change
B 31.6952 -9.44% -3.30
SNG closed up 31.09 percent on Monday, May 16, 2022, on 5.92 times normal volume.
Earnings due: May 25
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
New Uptrend Bullish -11.86%
Expansion Breakout Bullish Swing Setup -11.86%
Expansion Pivot Buy Setup Bullish Swing Setup -11.86%
Pocket Pivot Bullish Swing Setup -11.86%
Volume Surge Other -11.86%
Wide Range Bar Range Expansion -11.86%
Upper Bollinger Band Walk Strength -11.86%
Multiple of Ten Bearish Other -11.86%
Multiple of Ten Bullish Other -11.86%
Wide Bands Range Expansion -11.86%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
5x Volume Pace about 1 hour ago
3x Volume Pace about 1 hour ago
2x Volume Pace about 1 hour ago
1.5x Volume Pace about 1 hour ago
Down 10% about 2 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synairgen Plc Description

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Bank Medicine Clinic Disease Diseases Biology Therapy Beta Rtt Respirator Drug Discovery Therapies In Vitro Respiratory Disease Chronic Obstructive Pulmonary Disease Respiratory Diseases Respiratory Therapy Astrazeneca Fibrosis Asthma Chronic Lower Respiratory Diseases Copd

Is SNG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 223.8
52 Week Low 10.0
Average Volume 2,708,651
200-Day Moving Average 132.32
50-Day Moving Average 24.23
20-Day Moving Average 24.93
10-Day Moving Average 26.00
Average True Range 3.66
RSI 66.10
ADX 41.4
+DI 41.69
-DI 13.18
Chandelier Exit (Long, 3 ATRs) 33.00
Chandelier Exit (Short, 3 ATRs) 33.00
Upper Bollinger Bands 30.06
Lower Bollinger Band 19.81
Percent B (%b) 1.48
BandWidth 41.12
MACD Line -0.67
MACD Signal Line -2.23
MACD Histogram 1.5614
Fundamentals Value
Market Cap 69.97 Million
Num Shares 200 Million
EPS -3.40
Price-to-Earnings (P/E) Ratio -10.29
Price-to-Sales 759.00
Price-to-Book 24.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.90
Resistance 3 (R3) 60.13 52.05 55.75
Resistance 2 (R2) 52.05 45.71 51.94 54.37
Resistance 1 (R1) 43.53 41.79 47.79 43.30 52.98
Pivot Point 35.45 35.45 37.59 35.34 35.45
Support 1 (S1) 26.93 29.11 31.19 26.70 17.02
Support 2 (S2) 18.85 25.19 18.74 15.63
Support 3 (S3) 10.33 18.85 14.25
Support 4 (S4) 10.10